Site-dependent degradation of a non-cleavable auristatin-based linker-payload in rodent plasma and its effect on ADC efficacy

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Dorywalska, Magdalena ^a   Strop, Pavel ^a   Melton Witt, Jody A ^a   Hasa Moreno, Adela ^a   Farias, Santiago E ^a   Casas, Meritxell Galindo ^a   Delaria, Kathy ^a   Lui, Victor ^a   Poulsen, Kris ^a   Sutton, Janette ^a   Bolton, Gary ^a   Zhou, Dahui ^a   Moine, Ludivine ^a   Dushin, Russell ^a   Tran, Thomas Toan ^a   Liu, Shu Hui ^a   Rickert, Mathias ^a   Foletti, Davide ^a   Shelton, David L ^a   Pons, Jaume ^a   Rajpal, Arvind ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; AMINOBENZOIC ACID DERIVATIVE; ANTIBODY; AURISTATIN; DRUG CARRIER; OLIGOPEPTIDE;

ANIMAL CELL; ARTICLE; CANCER CELL; CATALYSIS; CONCENTRATION RESPONSE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; ENZYME DEGRADATION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; NONHUMAN; PROTEIN CLEAVAGE; ANIMAL; CHEMISTRY; DRUG STABILITY; FEMALE; HEK293 CELL LINE; MACACA FASCICULARIS; RAT; SCID MOUSE;

AMINOBENZOATES; ANIMALS; ANTIBODIES; DRUG CARRIERS; DRUG STABILITY; FEMALE; HEK293 CELLS; HUMANS; MACACA FASCICULARIS; MICE, SCID; OLIGOPEPTIDES; RATS;

EID: 84941313033     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132282     Document Type: Article

References (30)

1. Lambert JM. Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol. 2013;76(2):248-62. doi: 10.1111/bcp. 12044 PMID: 23173552; PubMed Central PMCID: PMC3731599.
2. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med. 2013;64:15-29. doi: 10.1146/annurev-med-050311-201823 PMID: 23043493.
3. Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancertherapy. MAbs. 2014;6(1):34-45. doi: 10.4161/mabs.27022 PMID: 24423619.
4. Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. BioconjugChem. 2010;21(1):5-13. Epub 2009/09/23. doi: 10.1021/bc9002019 PMID: 19769391.
5. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. NatBiotechnol. 2003;21(7):778-84. Epub 2003/06/05. doi: 10.1038/nbt832 [pii]. PMID: 12778055.
6. Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006;17(1):114-24. doi: 10.1021/bc0502917 PMID: 16417259.
7. Rostami S, Qazi I, Sikorski R. The Clinical Landscape of Antibody-drug Conjugates. J Antibody Drug Conjugates. 2014.
8. Jackson D, Stover D. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates. Pharm Res. 2014. doi: 10.1007/s11095-014-1536-7 PMID: 25339341.
9. McCombs JR, Owen SC. Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry. AAPS J. 2015. doi: 10.1208/s12248-014-9710-8 PMID: 25604608.
10. Sanderson RJ, Hering MA, James SF, Sun MM, Doronina SO, Siadak AW, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res. 2005;11(2 Pt 1):843-52. Epub 2005/02/11.11/2/843 [pii]. PMID: 15701875.
11. Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem. 2008;19(3):759-65. Epub 2008/03/05. doi: 10.1021/bc7004329 PMID: 18314937.
12. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012;30(2):184-9. Epub 2012/01/24. doi: 10.1038/nbt.2108 PMID: 22267010.
13. Pillow TH, Tien J, Parsons-Reponte KL, Bhakta S, Li H, Staben LR, et al. Site-specifictrastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering. J Med Chem. 2014;57(19):7890-9. doi: 10.1021/jm500552c PMID: 25191794.
14. Tumey LN, Charati M, He T, Sousa E, Ma D, Han X, et al. Mild Method for Succinimide Hydrolysis on ADCs: Impact on ADC Potency, Stability, Exposure, and Efficacy. Bioconjug Chem. 2014;25(10):1871-80. doi: 10.1021/bc500357n PMID: 25216346.
15. Lyon RP, Setter JR, Bovee TD, Doronina SO, Hunter JH, Anderson ME, et al. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nat Biotechnol. 2014;32(10):1059-62. doi: 10.1038/nbt.2968 PMID: 25194818.
16. Strop P, Dorywalska M, Rajpal A, Shelton DL, Liu S-H, Pons J, et al., inventors; Patent WO2012059882, assignee. Engineered polypeptide conjugates and methods for making thereof using transglutaminase patent WO2012059882. 2012.
17. Strop P, Liu SH, Dorywalska M, Delaria K, Dushin RG, Tran TT, et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol. 2013;20(2):161-7. Epub 2013/02/27. doi: 10.1016/j.chembiol.2013.01.010 PMID: 23438745.
18. Jeger S, Zimmermann K, Blanc A, Grunberg J, Honer M, Hunziker P, et al. Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew Chem Int Ed Engl. 2010;49(51):9995-7. Epub 2010/11/27. doi: 10.1002/anie.201004243 PMID: 21110357.
19. Dennler P, Chiotellis A, Fischer E, Bregeon D, Belmant C, Gauthier L, et al. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates. Bioconjug Chem. 2014;25(3):569-78. doi: 10.1021/bc400574z PMID: 24483299.
20. Farias SE, Strop P, Delaria K, Galindo Casas M, Dorywalska M, Shelton DL, et al. Massspectrometric characterization of transglutaminase based site-specific antibody-drug conjugates. Bioconjug Chem. 2014;25(2):240-50. doi: 10.1021/bc4003794 PMID: 24359082.
21. Dorywalska M, Strop P, Melton-Witt JA, Hasa-Moreno A, Farias SE, Galindo Casas M, et al. Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates. Bioconjug Chem. 2015. doi: 10. 1021/bc5005747 PMID: 25643134.
22. Pettit GR, Kamano Y, Herald CL, Tuinman AA, Boettner FE, Kizu H, et al. The Isolation and Structure of a Remarkable Marine Animal Antineoplastic Constituent: Dolastatin 10. J Am Chem Soc. 1987;109:6883-5.
23. Maderna A, Doroski M, Subramanyam C, Porte A, Leverett CA, Vetelino BC, et al. Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications. J Med Chem. 2014;57(24):10527-43. doi: 10.1021/jm501649k PMID: 25431858.
24. Roche. The Complete Guide for Protease Inhibition.
25. Sigma-Aldrich. Protease Inhibition and Detection. Life Science BioFiles. 2009;4 (2).
26. Smyth DG, Blumenfeld OO, Konigsberg W. Reactions of N-ethylmaleimide with peptides and amino acids. Biochem J. 1964;91(3):589-95. PMID: 5840721; PubMed Central PMCID: PMC1202996.
27. Bender B, Leipold DD, Xu K, Shen BQ, Tibbitts J, Friberg LE. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer. AAPS J. 2014;16(5):994-1008. doi: 10.1208/s 12248-014-9618-3 PMID: 24917179; PubMed Central PMCID: PMC4147041.
28. Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, et al. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res. 2010;16(19):4769-78. doi: 10.1158/1078-0432. CCR-10-0987 PMID: 20805300.
29. Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol. 2012;69(5):1229-40. doi: 10.1007/s00280-011-1817-3 PMID: 22271209; PubMed Central PMCID: PMC3337408.
30. Tannir NM, Forero-Torres A, Ramchandren R, Pal SK, Ansell SM, Infante JR, et al. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs. 2014;32(6):1246-57. doi: 10.1007/s10637-014-0151-0 PMID: 25142258.